Abstract:G protein-coupled receptor 40 (GPR40) is predominantly expressed in pancreatic β-cells and activated by long-chain fatty acids. GPR40 has drawn considerable interest as a potential therapeutic target for type 2 diabetes mellitus (T2DM) due to its important role in enhancing glucose-stimulated insulin secretion (GSIS). Encouragingly, GPR40 is also proven to be highly expressed in glucagon-like peptide-1 (GLP-1)-producing enteroendocrine cells afterwards, which opens a potential role of GPR40 in enhancing GLP-1 secretion to exert additional anti-diabetic efficacy. In the present study, we discovered a novel GPR40 agonist, yhhu4488, which is structurally different from other reported GPR40 agonists. Yhhu4488 showed potent agonist activity with EC50 of 49.96 nM, 70.83 nM and 58.68 nM in HEK293 cells stably expressing human, rat and mouse GPR40, respectively. Yhhu4488 stimulated GLP-1 secretion from fetal rat intestinal cells (FRIC) via triggering endogenous calcium store mobilization and extracellular calcium influx. The effect of yhhu4488 on GLP-1 secretion was further confirmed in type 2 diabetic db/db mice. Yhhu4488 exhibited satisfactory potency in in vivo studies. Single administration of yhhu4488 improved glucose tolerance in SD rats. Chronic administration of yhhu4488 effectively decreased fasting blood glucose level, improved β-cell function and lipid homeostasis in type 2 diabetic ob/ob mice. Taken together, yhhu4488 is a novel GPR40 agonist that enhances GLP-1 secretion, improves metabolic control and β-cell function, suggesting its promising potential for the treatment of type 2 diabetes.

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Discovery of Orally Effective and Safe GPR40 Agonists by Incorporating a Chiral, Rigid and Polar Sulfoxide into Β-Position to the Carboxylic Acid.

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into 8-position to the carboxylic acid

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Advances in Small-Molecule GPR40 Agonists for Treatment of Type 2 Diabetes Mellitus

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: the Biological Characteristics and the Chemical Space

Optimization of GPR40 Agonists for Type 2 Diabetes.

Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Discovery of Pyrrolidine-Containing Gpr40 Agonists: Stereochemistry Effects A Change in Binding Mode

Discovery of Benzofuran Propanoic Acid GPR120 Agonists: from Uhts Hit to Mechanism-Based Pharmacodynamic Effects.

Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models

Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Discovery of Novel Free Fatty Acid Receptor 1 Agonists Bearing Triazole Core Via Click Chemistry